Michael L. Goris

Publications

• Safety of Repeated Yttrium-90 Radioembolization. Lam MG, Louie JD, Iagaru AH, Goris ML, Sze DY. Cardiovasc Intervent Radiol. 2013
• Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease. Blankenberg FG, Kinsman SL, Cohen BH, Goris ML, Spicer KM, Perlman SL, Krane EJ, Kheifets V, Thoolen M, Miller G, Enns GM. Mol Genet Metab. 2012; 107 (4): 690-9
• Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Natarajan A, Gowrishankar G, Nielsen CH, Wang S, Iagaru A, Goris ML, Gambhir SS. Mol Imaging Biol. 2012; 14 (5): 608-16
• Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS. Radiology. 2011; 260 (1): 182-91
• Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. Blankenberg FG, Levashova Z, Goris MG, Hamby CV, Backer MV, Backer JM. J Nucl Med. 2011; 52 (10): 1630-7
• 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. Mol Imaging Biol. 2010; 12 (2): 198-203
• Combined 18F-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future? Iagaru A, Mittra E, Goris ML, Gambhir SS. J Nucl Med. 2009
• Endogenous NIS expression in triple-negative breast cancers. Renier C, Yao C, Goris M, Ghosh M, Katznelson L, Nowles K, Gambhir SS, Wapnir I. Ann Surg Oncol. 2009; 16 (4): 962-8
• Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. Louie JD, Kothary N, Kuo WT, Hwang GL, Hofmann LV, Goris ML, Iagaru AH, Sze DY. J Vasc Interv Radiol. 2009; 20 (5): 606-13
• Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, Gambhir SS. J Nucl Med. 2009; 50 (4): 501-5
• Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Robinson TE, Trapnell BC, Goris ML, Quittell LM, Cornfield DN. Chest. 2009; 135 (3): 842-8
• Sampling density for the quantitative evaluation of air trapping. Goris ML, Robinson TE. Pediatr Radiol. 2009; 39 (3): 221-5
• Tumor Metabolic Phenotypes on 18F FDG PET. Iagaru AH, Gambhir SS, Goris ML. J Nucl Med. 2009
• (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Iagaru A, Wang Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. Hell J Nucl Med. 2008 Sep-Dec; 11 (3): 153-6
• 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. Iagaru A, Gambhir SS, Goris ML. J Nucl Med. 2008; 49 (11): 1809-12
• Perspectives of molecular imaging and radioimmunotherapy in lymphoma. Iagaru A, Goris ML, Gambhir SS. Radiol Clin North Am. 2008; 46 (2): 243-52, viii
• Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by (18)F-18 FDG PET/CT and bone marrow biopsy. Iagaru A, Goris ML. Eur J Nucl Med Mol Imaging. 2008; 35 (9): 1746
• Evaluation of herpes simplex virus 1 thymidine kinase-mediated trapping of (131)I FIAU and prodrug activation of ganciclovir as a synergistic cancer radio/chemotherapy. Schipper ML, Goris ML, Gambhir SS. Mol Imaging Biol. 2007 May-Jun; 9 (3): 110-6
• A critical discussion of computer analysis in medical imaging. Goris ML, Zhu HJ, Robinson TE. Proc Am Thorac Soc. 2007; 4 (4): 347-9
• Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, Yenari MA. J Nucl Med. 2007; 48 (11): 1822-8
• Bioluminescent monitoring of NIS-mediated (131)I ablative effects in MCF-7 xenografts. Ghosh M, Gambhir SS, De A, Nowels K, Goris M, Wapnir I. Mol Imaging. 2006 Apr-Jun; 5 (2): 76-84
• 99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Blankenberg FG, Kalinyak J, Liu L, Koike M, Cheng D, Goris ML, Green A, Vanderheyden JL, Tong DC, Yenari MA. Eur J Nucl Med Mol Imaging. 2006; 33 (5): 566-74
• Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ. Cancer Biother Radiopharm. 2006; 21 (3): 243-56
• Relative lung perfusion distribution in normal lung scans: observations and clinical implications. Cheng CP, Taur AS, Lee GS, Goris ML, Feinstein JA. Congenit Heart Dis. 2006; 1 (5): 210-6
• Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Chest. 2005; 128 (4): 2327-35
• Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. J Clin Oncol. 2005; 23 (4): 712-9
• Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V. Mari C, Karabiyikoglu M, Goris ML, Tait JF, Yenari MA, Blankenberg FG. Eur J Nucl Med Mol Imaging. 2004; 31 (5): 733-9
• Pericardial lymph node involvement in lymphoma as identified on PET. Franc B, Yoshida E, Herfkens R, Goris M. Clin Nucl Med. 2004; 29 (11): 741-2
• The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, Carrasco N. Clin Cancer Res. 2004; 10 (13): 4294-302
• The radioisotope contributes significantly to the activity of radioimmunotherapy. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. Clin Cancer Res. 2004; 10 (23): 7792-8
• An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Goris ML, Zhu HJ, Blankenberg F, Chan F, Robinson TE. Chest. 2003; 123 (5): 1655-63
• Positively labeled white blood cell scan with eosinophilia and absence of infection. Vasanawala MS, Goris ML. Clin Nucl Med. 2003; 28 (5): 389-91
• Low uptake of Tc-99m tetrofosmin in lung cancer: a case report. Franc B, Goris M. Clin Nucl Med. 2002; 27 (10): 698-700
• Therapeutic lymphangiogenesis with human recombinant VEGF-C. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. FASEB J. 2002; 16 (14): 1985-7
• In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V. Kown MH, Strauss HW, Blankenberg FG, Berry GJ, Stafford-Cecil S, Tait JF, Goris ML, Robbins RC. Am J Transplant. 2001; 1 (3): 270-7
• Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. Clin Cancer Res. 2000; 6 (2): 406-14
• Three-Dimensional Quantitative Analysis of Scintigraphic Tomographic Images after Elastic Transformation to a Template. Goris ML, Maclean M, Pace WM, Yee A, Kwan A. Surg Technol Int. 2000: IX 81-90
• Factors affecting and computation of myocardial perfusion reference images. Goris ML, Hotz B, Thirion JP, Similon P. Nucl Med Commun. 1999; 20 (7): 627-35
• [Preliminary evaluation of the effect of an attenuation correction method in myocardial perfusion SPECT]. Cortés-Blanco A, Fujii C, Goris ML. Rev Esp Med Nucl. 1999; 18 (6): 416-24
• Pulmonary SPECT imaging and the stripe sign. Pace WM, Goris ML. J Nucl Med. 1998; 39 (4): 721-3
• MRI of pulmonary embolism using Gd-DTPA-polyethylene glycol polymer enhanced 3D fast gradient echo technique in a canine model. Li KC, Pelc LR, Napel SA, Goris ML, Lin DT, Song CK, Leung AN, Rubin GD, Hollett MD, Harris DP. Magn Reson Imaging. 1997; 15 (5): 543-50
• Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-López A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R. Clin Cancer Res. 1996; 2 (3): 457-70
• Modelling the integration of myocardial regional perfusion and function. Goris ML, Thompson C, Malone LJ, Franken PR. Nucl Med Commun. 1994; 15 (1): 9-20
• Organ modeling in the quantitation of planar images for distribution studies. Goris ML, Knox SA, Nielsen KR, Bouillant O. Cancer. 1994; 73 (3 Suppl): 919-22
• The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Wilder RB, McGann JK, Sutherland WR, Waller EK, Minchinton AI, Goris ML, Knox SJ. Int J Radiat Oncol Biol Phys. 1994; 28 (1): 119-26
• Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Knox SJ, Sutherland W, Goris ML. Radiat Res. 1993; 135 (1): 24-31
• Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ. Cancer Res. 1993; 53 (13): 3022-7
• Case report: diffuse gastrointestinal bleeding. Goris ML, Licho R. Am J Physiol Imaging. 1992 Jan-Mar; 7 (1): 42-3
• Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Knox SJ, Goris ML, Wessels BW. Radiother Oncol. 1992; 23 (2): 111-7
• The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma. Schiele J, Knox SJ, Ruehl W, Goris ML. Radiother Oncol. 1992; 24 (3): 169-76
• Long-term scintigraphic appearance of extremities following bone tumor resection and allograft reconstruction. Smith JT, Smith LM, Rinsky L, Goris ML. Clin Nucl Med. 1991; 16 (12): 907-9
• Parathyroid imaging. Goris ML, Basso LV, Keeling C. J Nucl Med. 1991; 32 (5): 887-9
• The biodistribution of 111In-anti-bFGF in a variety of tumors. Correlation with cell-binding assays. Knox SJ, Brown JM, McGann J, Sutherland W, Goris ML, Herblin WF, Gross JL. Ann N Y Acad Sci. 1991: 638 497-502
• The quantification of planar scintigraphy using three dimensional modelling of organ shadows. Goris ML, Prog Clin Biol Res. 1991: 363 531-9
• Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini P, Goris ML. Cancer Res. 1990; 50 (16): 4935-40
• Validation of diagnostic procedures on stratified populations: application on the quantification of thallium myocardial perfusion scintigraphy. Goris ML, Bretille J, Askienazy S, Purcell GP, Savelli V. Am J Physiol Imaging. 1989; 4 (1): 11-5
• Noninvasive assessment of donor and native heart function after heterotopic heart transplantation. Allen MD, Naasz CA, Popp RL, Hunt SA, Goris ML, Oyer PE, Stinson EB. J Thorac Cardiovasc Surg. 1988; 95 (1): 75-81
• Two-dimensional mapping of three-dimensional SPECT data: a preliminary step to the quantitation of thallium myocardial perfusion single photon emission tomography. Goris ML, Boudier S, Briandet PA. Am J Physiol Imaging. 1987; 2 (4): 176-80
• Interrogation and display of single photon emission tomography data as inherently volume data. Goris ML, Boudier S, Briandet PA. Am J Physiol Imaging. 1986; 1 (4): 168-80